Jessie Hanrahan, Chief Regulatory Officer of Solid Biosciences Inc (NASDAQ:SLDB), sold 12,348 shares of common stock on February 4, 2026, for a total value of $79,544. The shares were sold at a weighted average price of $6.4419, with individual sales prices ranging from $6.28 to $6.60. The transaction comes as SLDB shares have posted an impressive 126% return over the past year, though InvestingPro data indicates the stock is currently trading slightly above its Fair Value with a market cap of approximately $508 million.
Following the transaction, Hanrahan directly owns 70,327 shares of Solid Biosciences Inc. common stock. The sale was executed to cover withholding taxes related to the vesting of restricted stock units, according to a footnote in the SEC filing. Investors should note that SLDB exhibits high volatility with a 5-year beta of 2.65, and the company is scheduled to report earnings on March 6. InvestingPro identifies several key factors for SLDB, including cash burn concerns and price volatility, with comprehensive analysis available in the Pro Research Report covering this biotech company.
In other recent news, Solid Biosciences Inc. has made significant advancements in its clinical trials and regulatory milestones. The company has dosed 33 participants in its Phase 1/2 INSPIRE DUCHENNE trial, reporting that the SGT-003 therapy is generally well tolerated with no significant adverse effects observed. Additionally, Solid Biosciences received Orphan Drug designation from the U.S. Food and Drug Administration for its investigational gene therapy SGT-212, targeting Friedreich’s ataxia. This designation coincides with the dosing of the first participant in its Phase 1b FALCON trial, which employs a dual-route administration approach.
The inclusion of Duchenne muscular dystrophy in the Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services is expected to enhance early detection and treatment access, a move supported by Solid Biosciences. In terms of market analysis, Citizens has reiterated a Market Outperform rating for Solid Biosciences, emphasizing the company’s proprietary capsid and unique dystrophin as competitive advantages. These developments highlight Solid Biosciences’ ongoing efforts in advancing treatments for rare diseases.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
